Neuroprotection Market Forecast to Double Within Six Years

The market for products that have a neuroprotective effect will rise to $5.1 billion by 2005 and more than double by 2010 to $11.5 billion, says a new report available from Piribo.

(PRWEB) October 28, 2004 -- Analysis in the report Neuroprotection - Drugs, Markets and Companies, shows that neuroprotective products have a market value of $1.8 billion out of a CNS market value of $24.4 billion. Neuroprotection has a crucial role to play in both the treatment of acute disorders such as stroke, traumatic brain injury and spinal cord injury and in the management of chronic diseases, including Alzheimer's, Parkinson's, Huntington's disease, multiple sclerosis and epilepsy.

The report describes the various roles of neuroprotection in the treatment and management of diseases and details the neuroprotective effects of over 300 products. The pathomechanisms of diseases are described, with steps at which neuroprotective therapies are directed.

The report contains a profile of 105 companies that have a neuroprotective product or products. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Clinical trials of various neuroprotective agents are described and failures of trials in stroke and head injury are analysed, with suggestions for improving the selection of drugs and design of trials.

Neuroprotection - Drugs, Markets and Companies is available from Piribo.

For more information visit: http://www.piribo.com/publications/therapeutic/cns_neurology/neuroprotection.html

About Piribo.

Piribo is the source for information products concerning the global biotechnology and pharmaceutical industries and contains details of hundreds of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer a current and comprehensive range of specialised intelligence.

###